OTCMKTS:SONVY - Sonova Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
6 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$56.72 As of 05/14/2021 01:00 AM ET

▲ +2.11 (3.86%)

1 month | 3 months | 12 months

Get New Sonova Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SONVY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SONVY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for Sonova in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $56.72.

Hold

The current consensus among 9 contributing investment analysts is to hold stock in Sonova. This rating has held steady since October 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

11/22/2019

0 strong buy ratings
1 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

2/20/2020

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

5/20/2020

0 strong buy ratings
1 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

8/18/2020

0 strong buy ratings
2 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

11/16/2020

0 strong buy ratings
2 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

2/14/2021

0 strong buy ratings
3 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

4/15/2021

0 strong buy ratings
3 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

5/15/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Details
3/24/2021	JPMorgan Chase & Co.	Reiterated Rating	Neutral	i
2/18/2021	Exane BNP Paribas	Upgrade	Underperform ➝ Outperform	i
2/2/2021	UBS Group	Reiterated Rating	Neutral	i
12/9/2020	Morgan Stanley	Reiterated Rating	Equal Weight	i
12/1/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	i
11/24/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral	i
11/23/2020	Berenberg Bank	Reiterated Rating	Hold	i
11/17/2020	Credit Suisse Group	Reiterated Rating	Outperform	i
11/17/2020	UBS Group	Reiterated Rating	Neutral	i
11/5/2020	Berenberg Bank	Reiterated Rating	Hold	i
10/8/2020	Credit Suisse Group	Reiterated Rating	Outperform	i
10/8/2020	Citigroup	Initiated Coverage	Neutral	i
9/30/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral	i
9/29/2020	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	i
9/29/2020	UBS Group	Reiterated Rating	Neutral	i
9/2/2020	UBS Group	Reiterated Rating	Neutral	i
7/27/2020	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	i
5/22/2020	UBS Group	Downgrade	Buy ➝ Neutral	i
5/21/2020	JPMorgan Chase & Co.	Upgrade	Neutral	i
5/20/2020	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	i
5/12/2020	Berenberg Bank	Reiterated Rating	Hold	i
4/17/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	i
4/9/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	i
1/5/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	i
10/31/2019	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	i
9/10/2019	Jefferies Financial Group	Upgrade	Hold ➝ Buy	i
1/14/2019	UBS Group	Upgrade	Neutral ➝ Buy	i
2/6/2017	UBS Group	Downgrade	Neutral ➝ Sell	i
9/29/2016	Credit Suisse Group	Reiterated Rating	Outperform	i

(Data available from 5/16/2016 forward)

Sonova Holding AG designs, develops, manufactures, and distributes hearing systems for adults and children with hearing impairment. It operates through two segments, Hearing Instruments and Cochlear Implants segments. It offers wireless communication products, rechargeable hearing aids, and professional audiological care services. The company provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; and professional hearing care services under the AudioNova, Audium, AuditionSantÃ©, Boots Hearingcare, Connect Hearing, Fiebing, Geers, Hansaton, Lapperre, Lindacher, Schoonenberg, Triton, and Vitakustik brands. Sonova Holding AG sells its products through wholesale companies and independent distributors; and provides professional audiological care services through a network of approximately 3,500 stores and clinics. It operates in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in StÃ¤fa, Switzerland.

Today's Range

Now: $56.72

$56.41

$56.88

50 Day Range

MA: $57.20

$52.99

$60.64

52 Week Range

Now: $56.72

$37.46

$60.76

Volume

38,570 shs

Average Volume

19,957 shs

Market Capitalization

$18.26 billion

P/E Ratio

38.06

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonova?

The following Wall Street sell-side analysts have issued reports on Sonova in the last twelve months: Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Exane BNP Paribas, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for SONVY.

What is the current price target for Sonova?

0 Wall Street analysts have set twelve-month price targets for Sonova in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sonova in the next year.
View the latest price targets for SONVY.

What is the current consensus analyst rating for Sonova?

Sonova currently has 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SONVY, but not buy more shares or sell existing shares.
View the latest ratings for SONVY.

What other companies compete with Sonova?

Other companies that are similar to Sonova include Varian Medical Systems, Masimo, Getinge, CONMED, LivaNova, InMode, Outset Medical, BioLife Solutions, Natus Medical, AxoGen, ViewRay, Semler Scientific, TransMedics Group, Cutera and Stereotaxis.

How do I contact Sonova's investor relations team?

Sonova's physical mailing address is Laubisrutistrasse 28, Stafa V8, 8712. The company's listed phone number is 41-58-928-3333 and its investor relations email address is [email protected] The official website for Sonova is www.sonova.com.